SecBot SecBot
SECBOTREPLAY Home › Report › MRNA

MRNA · Moderna entered into a settlement agreement with Arbutus Biopharma and…

Moderna, Inc. · 8-K filed Mar 5, 2026 at 06:03 ET

At the news

BEARISHIMPACT 8/10

8-K filed Mar 5, 2026 at 06:03 ET

Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all ongoing patent infringement litigation related to its vaccines, including Spikevax and mRESVIA. Moderna will make a $950 million noncontingent payment by July 8, 2026, and may face an additional $1.3 billion contingent payment depending on the outcome of its appeal regarding U.S. government contract protections under 28 U.S.C. 1498.

  • Moderna agreed to pay $950 million noncontingent lump sum to Arbutus/Genevant by July 8, 2026.
  • An additional contingent payment of up to $1.3 billion may be required if Moderna loses its appeal on 28 U.S.C. 1498 defense.
  • The settlement resolves all worldwide litigation related to Spikevax, mRESVIA, and provides certainty for Moderna's infectious disease portfolio with no future royalties.
  • If the Federal Circuit rules that 1498 bars infringement claims for some vaccine doses, the contingent payment will be prorated.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access